Auswahl der wissenschaftlichen Literatur zum Thema „Metabolomic signature“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Inhaltsverzeichnis
Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "Metabolomic signature" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Zeitschriftenartikel zum Thema "Metabolomic signature"
Szczerbinski, Lukasz, Gladys Wojciechowska, Adam Olichwier, Mark A. Taylor, Urszula Puchta, Paulina Konopka, Adam Paszko et al. „Untargeted Metabolomics Analysis of the Serum Metabolic Signature of Childhood Obesity“. Nutrients 14, Nr. 1 (04.01.2022): 214. http://dx.doi.org/10.3390/nu14010214.
Der volle Inhalt der QuelleBever, Alaina M., Dong Hang, Amit D. Joshi, Connor M. Geraghty, Dong Hoon Lee, Fred K. Tabung, Shuji Ogino et al. „Abstract 3006: Metabolomic signatures of metabolic disturbance and inflammation in relation to colorectal cancer risk“. Cancer Research 83, Nr. 7_Supplement (04.04.2023): 3006. http://dx.doi.org/10.1158/1538-7445.am2023-3006.
Der volle Inhalt der QuelleYang, Mingjia, Chen Zhu, Lingbin Du, Jianv Huang, Jiayi Lu, Jing Yang, Ye Tong et al. „A Metabolomic Signature of Obesity and Risk of Colorectal Cancer: Two Nested Case–Control Studies“. Metabolites 13, Nr. 2 (05.02.2023): 234. http://dx.doi.org/10.3390/metabo13020234.
Der volle Inhalt der QuelleDavis, Vanessa Wylie, Dan E. Schiller und Michael B. Sawyer. „Metabolomic signature of esophageal cancer.“ Journal of Clinical Oncology 30, Nr. 4_suppl (01.02.2012): 21. http://dx.doi.org/10.1200/jco.2012.30.4_suppl.21.
Der volle Inhalt der QuelleLokhov, Petr G., Oxana P. Trifonova, Dmitry L. Maslov und Elena E. Balashova. „In Situ Mass Spectrometry Diagnostics of Impaired Glucose Tolerance Using Label-Free Metabolomic Signature“. Diagnostics 10, Nr. 12 (05.12.2020): 1052. http://dx.doi.org/10.3390/diagnostics10121052.
Der volle Inhalt der QuelleLi, Zhen, Yue Mu, Chunlan Guo, Xin You, Xiaoyan Liu, Qian Li und Wei Sun. „Analysis of the saliva metabolic signature in patients with primary Sjögren’s syndrome“. PLOS ONE 17, Nr. 6 (02.06.2022): e0269275. http://dx.doi.org/10.1371/journal.pone.0269275.
Der volle Inhalt der QuelleStockard, Bradley, Timothy Garrett, Soheil Meshinchi und Jatinder K. Lamba. „Metabolomic Profiling Defines Distinct Metabolic Signature Associated with FLT3/ITD AML“. Blood 128, Nr. 22 (02.12.2016): 1692. http://dx.doi.org/10.1182/blood.v128.22.1692.1692.
Der volle Inhalt der QuelleSerri, Orianne, Magalie Boguenet, Juan Manuel Chao de la Barca, Pierre-Emmanuel Bouet, Hady El Hachem, Odile Blanchet, Pascal Reynier und Pascale May-Panloup. „A Metabolomic Profile of Seminal Fluid in Extremely Severe Oligozoopermia Suggesting an Epididymal Involvement“. Metabolites 12, Nr. 12 (15.12.2022): 1266. http://dx.doi.org/10.3390/metabo12121266.
Der volle Inhalt der QuellePutluri, N., Y. Zhang, V. Putluri, S. Vareed, V. T. Vasu, S. M. Fischer, C. Chad und A. Sreekumar. „Androgen-regulated metabolome in prostate cancer.“ Journal of Clinical Oncology 29, Nr. 7_suppl (01.03.2011): 25. http://dx.doi.org/10.1200/jco.2011.29.7_suppl.25.
Der volle Inhalt der QuelleTroisi, Jacopo, Laura Sarno, Annamaria Landolfi, Giovanni Scala, Pasquale Martinelli, Roberta Venturella, Annalisa Di Cello, Fulvio Zullo und Maurizio Guida. „Metabolomic Signature of Endometrial Cancer“. Journal of Proteome Research 17, Nr. 2 (02.01.2018): 804–12. http://dx.doi.org/10.1021/acs.jproteome.7b00503.
Der volle Inhalt der QuelleDissertationen zum Thema "Metabolomic signature"
Rocha, Cláudia Manuela Mesquita da. „Metabolic signature of lung cancer: a metabolomic study of human tissues and biofluids“. Doctoral thesis, Universidade de Aveiro, 2015. http://hdl.handle.net/10773/13957.
Der volle Inhalt der QuelleThis thesis reports the application of metabolomics to human tissues and biofluids (blood plasma and urine) to unveil the metabolic signature of primary lung cancer. In Chapter 1, a brief introduction on lung cancer epidemiology and pathogenesis, together with a review of the main metabolic dysregulations known to be associated with cancer, is presented. The metabolomics approach is also described, addressing the analytical and statistical methods employed, as well as the current state of the art on its application to clinical lung cancer studies. Chapter 2 provides the experimental details of this work, in regard to the subjects enrolled, sample collection and analysis, and data processing. In Chapter 3, the metabolic characterization of intact lung tissues (from 56 patients) by proton High Resolution Magic Angle Spinning (HRMAS) Nuclear Magnetic Resonance (NMR) spectroscopy is described. After careful assessment of acquisition conditions and thorough spectral assignment (over 50 metabolites identified), the metabolic profiles of tumour and adjacent control tissues were compared through multivariate analysis. The two tissue classes could be discriminated with 97% accuracy, with 13 metabolites significantly accounting for this discrimination: glucose and acetate (depleted in tumours), together with lactate, alanine, glutamate, GSH, taurine, creatine, phosphocholine, glycerophosphocholine, phosphoethanolamine, uracil nucleotides and peptides (increased in tumours). Some of these variations corroborated typical features of cancer metabolism (e.g., upregulated glycolysis and glutaminolysis), while others suggested less known pathways (e.g., antioxidant protection, protein degradation) to play important roles. Another major and novel finding described in this chapter was the dependence of this metabolic signature on tumour histological subtype. While main alterations in adenocarcinomas (AdC) related to phospholipid and protein metabolisms, squamous cell carcinomas (SqCC) were found to have stronger glycolytic and glutaminolytic profiles, making it possible to build a valid classification model to discriminate these two subtypes. Chapter 4 reports the NMR metabolomic study of blood plasma from over 100 patients and near 100 healthy controls, the multivariate model built having afforded a classification rate of 87%. The two groups were found to differ significantly in the levels of lactate, pyruvate, acetoacetate, LDL+VLDL lipoproteins and glycoproteins (increased in patients), together with glutamine, histidine, valine, methanol, HDL lipoproteins and two unassigned compounds (decreased in patients). Interestingly, these variations were detected from initial disease stages and the magnitude of some of them depended on the histological type, although not allowing AdC vs. SqCC discrimination. Moreover, it is shown in this chapter that age mismatch between control and cancer groups could not be ruled out as a possible confounding factor, and exploratory external validation afforded a classification rate of 85%. The NMR profiling of urine from lung cancer patients and healthy controls is presented in Chapter 5. Compared to plasma, the classification model built with urinary profiles resulted in a superior classification rate (97%). After careful assessment of possible bias from gender, age and smoking habits, a set of 19 metabolites was proposed to be cancer-related (out of which 3 were unknowns and 6 were partially identified as N-acetylated metabolites). As for plasma, these variations were detected regardless of disease stage and showed some dependency on histological subtype, the AdC vs. SqCC model built showing modest predictive power. In addition, preliminary external validation of the urine-based classification model afforded 100% sensitivity and 90% specificity, which are exciting results in terms of potential for future clinical application. Chapter 6 describes the analysis of urine from a subset of patients by a different profiling technique, namely, Ultra-Performance Liquid Chromatography coupled to Mass Spectrometry (UPLC-MS). Although the identification of discriminant metabolites was very limited, multivariate models showed high classification rate and predictive power, thus reinforcing the value of urine in the context of lung cancer diagnosis. Finally, the main conclusions of this thesis are presented in Chapter 7, highlighting the potential of integrated metabolomics of tissues and biofluids to improve current understanding of lung cancer altered metabolism and to reveal new marker profiles with diagnostic value.
A presente tese reporta a aplicação da metabolómica ao estudo de tecidos e biofluidos humanos (plasma sanguíneo e urina), com o intuito de caracterizar a assinatura metabólica do cancro pulmonar primário. No Capítulo 1, apresenta-se uma breve introdução sobre a epidemiologia e a patogénese deste tipo de cancro, bem como um sumário das principais alterações metabólicas tipicamente associadas ao cancro em geral. Descreve-se ainda a abordagem metabolómica, nomeadamente os métodos analíticos e estatísticos utilizados, assim como o estado da arte da sua aplicação em estudos clínicos do cancro do pulmão. No Capítulo 2, apresentam-se os detalhes experimentais deste trabalho, no que diz respeito ao grupo de indivíduos envolvidos, à colheita e análise das amostras e ao posterior tratamento dos dados. O Capítulo 3 descreve a caracterização metabólica de tecidos do pulmão (de 56 doentes) por espetroscopia de Ressonância Magnética Nuclear (RMN) de alta resolução com rotação no ângulo mágico. Após a otimização cuidada das condições de aquisição e a identificação detalhada dos sinais espetrais (mais de 50 metabolitos identificados), os perfis metabólicos dos tumores e dos tecidos adjacentes não envolvidos (controlos) foram comparados por análise multivariada, tendo sido discriminados com uma exatidão de 97%. Os metabolitos que mais significativamente contribuíram para esta diferenciação foram: glucose e acetato (diminuídos nos tumores), lactato, alanina, glutamato, GSH, taurina, creatina, fosfocolina, glicerofosfocolina, fosfoetanolamina, nucleótidos de uracilo e péptidos (aumentados nos tumores). Algumas destas variações corroboraram alterações típicas do metabolismo do cancro (e.g., glicólise e glutaminólise aumentadas), enquanto outras sugeriram novas pistas sobre a possível relevância de processos como a proteção antioxidante e a degradação proteica. Um outro resultado novo e importante descrito neste capítulo foi a dependência da assinatura metabólica em relação ao tipo histológico do tumor. Enquanto as principais alterações observadas nos adenocarcinomas (AdC) se relacionaram com o metabolismo fosfolipídico e proteico, os carcinomas de células escamosas (SqCC) apresentaram perfis glicolíticos e glutaminolíticos mais pronunciados, sendo possível construir um modelo válido para a discriminação destes subtipos. No Capítulo 4, apresenta-se o estudo metabolómico por RMN de plasma sanguíneo de mais de 100 doentes e quase 100 controlos saudáveis, do qual resultou um modelo multivariado com uma taxa de classificação de 87%. A distinção entre os grupos foi feita essencialmente com base nos níveis de lactato, piruvato, acetoacetato, lipoproteínas LDL+VLDL e glicoproteínas (aumentados nos doentes), juntamente com os níveis de glutamina, histidina, valina, metanol, lipoproteínas HDL e dois compostos não identificados (diminuídos nos doentes). Estas variações foram detetadas desde os estádios iniciais da doença e a magnitude de algumas delas dependeu do tipo histológico, embora não permitindo discriminar AdC de SqCC. Para além disso, mostra-se neste capítulo que o desequilíbrio dos grupos controlo e cancro em termos da idade dos indivíduos poderá ter alguma influência nos resultados, e apresenta-se uma tentativa exploratória de validação externa, que resultou numa taxa de classificação de 85%. O estudo por RMN do perfil metabólico da urina dos doentes com cancro do pulmão e dos controlos é apresentado no Capítulo 5. Comparativamente ao plasma, o modelo construído com os perfis urinários apresentou uma taxa de classificação superior (97%). Após uma avaliação cuidada da possível influência do género, idade e hábitos tabágicos, um conjunto de 19 metabolitos foi proposto como estando relacionado com a doença (incluindo 3 compostos desconhecidos e 6 parcialmente identificados como metabolitos N-acetilados). Tal como no caso do plasma, estas variações foram detetadas em doentes no estádio inicial e mostraram alguma dependência em relação ao tipo histológico, obtendo-se um modelo válido para a discriminação AdC vs. SqCC, ainda que com um poder preditivo modesto. Para além disso, o teste preliminar de validação externa revelou 100% de sensibilidade e 90% de especificidade, o que é um resultado bastante promissor em termos da potencial utilização dos perfis urinários em aplicações clínicas futuras. No Capitulo 6, descreve-se a caracterização dos perfis metabólicos da urina (de um subgrupo de indivíduos) por cromatografia líquida de ultra-eficiência acoplada a espetrometria de massa (UPLC-MS). Embora não avançando muito na identificação estrutural de possíveis marcadores, este estudo reforçou o valor diagnóstico da urina, já que os modelos multivariados resultantes apresentaram taxa de classificação e poder preditivo elevados. Finalmente, no Capítulo 7, apresentam-se as principais conclusões deste trabalho, realçando o contributo da metabolómica integrada de tecidos e biofluidos para a compreensão do metabolismo alterado do cancro do pulmão e para a deteção de novos perfis marcadores com valor diagnóstico.
Miljanović, Nina [Verfasser], und Heidrun [Akademischer Betreuer] Potschka. „Proteomic and metabolomic signature of Dravet Syndrome : analysis in a genetic Scn1a-A1783V mouse model / Nina Miljanović ; Betreuer: Heidrun Potschka“. München : Universitätsbibliothek der Ludwig-Maximilians-Universität, 2021. http://d-nb.info/1239049420/34.
Der volle Inhalt der QuelleChao, de la Barca Juan Manuel. „Approche métabolomique des maladies dégénératives de la rétine et du nerf optique. : neuropathie optique héréditaire de Leber, athropie optique dominante et préconditionnement rétinien induit par la lumière The metabolomic signature of Leber's hereditary optic neuropathy reveals endoplasmic reticulum stress Metabolic signature of remote ischemic preconditioning involving a cocktail of amino acids and biogenic amines“. Thesis, Angers, 2016. http://www.theses.fr/2016ANGE0069.
Der volle Inhalt der QuelleWe have conducted a mass spectrometry targeted metabolomics approach, enabling us to quantify 188 metabolites including lipids and more polar molecules. Three condition related to the retina and the optic nerve have been studied: Leber hereditary optic neuropathy (LHON), dominant optic atrophy (DOA) due to OPA1 haploinsufficiency and retina light-induced preconditioning (RLIP). The main results we obtained are: LHON project: Concentrations of the whole pool of amino acid and some sphingomyelins (SM) were diminished whereas those of ten phosphatidylcholines (PC)were increased in fibroblasts carrying a LHON mutation. Fibroblasts from LHON-affected patients showed pharmacologically reversible endoplasmic reticulum stress. DOA project: Variations in the concentration of some lipids, glutamate and polar neuroprotective metabolites suggested pre-symptomatic alterations of the myelin sheath along with axonal metabolic dysfunction of the optic nerve in Opa1 +/-mice. A sexual dimorphism was also observed in the metabolome of the optic nerve. RLIP project: Preconditioning light seemed to elicit acute proteolysis and decreased NO production in the retina. Light stress was also related with lipid remodeling in the retina. A sexual dimorphism was also observed in the retina of control rats. Taken as a whole, our results show that the metabolomics approach is adapted and relevant for the study of the physiopathology of ocular diseases
Vives, Usano Marta 1990. „Prenatal and postnatal exposure to tobacco smoking and molecular signatures in children“. Doctoral thesis, Universitat Pompeu Fabra, 2018. http://hdl.handle.net/10803/665799.
Der volle Inhalt der QuelleFumar durant l’embaràs i l’exposició a tabac passiu de manera postnatal són preocupacions en la salut pública que estan associades a conseqüències adverses en la salut infantil, però poc se sap sobre els mecanismes moleculars. Hem investigat l’associació entre fumar durant l’embaràs i la metilació de l’ADN placentari, i la seva relació amb les conseqüències reproductives a través d’un meta-anàlisi. Hem identificat 1224 CpGs diferencialment metilats a placenta, enriquits en vies relacionades amb inflamació, factors de creixement i vascularització. A més a més, la metilació de molts CpGs està associada a l’edat gestacional i les mides al naixement. Hem investigat també l’associació entre fumar durant l’embaràs i l’exposició a tabac passiu de manera postnatal, i diferents capes moleculars en nens: metilació de l’ADN i transcripció en sang, proteïnes en plasma, metabòlits en sèrum i orina. L’exposició uterina, estava només associada amb la metilació de l’ADN del nen, confirmant un efecte persistent del patró de l’epigenoma en sang. Tot i això, aquesta empremta no es veu reflectida en el transcriptoma. En canvi, l’exposició a tabac passiu estava relacionada amb proteïnes i metabòlits, que són més dinàmics, i reflecteixen efectes a més curt termini. Hem observat també que el patró de metilació és específic de teixit.
Lu, YongPing [Verfasser]. „Maternal and fetal metabolomic signatures in regard to birth outcome and gestational disease / YongPing Lu“. Berlin : Medizinische Fakultät Charité - Universitätsmedizin Berlin, 2018. http://d-nb.info/1176636332/34.
Der volle Inhalt der QuelleKnacke, Henrike [Verfasser], Nele [Akademischer Betreuer] Friedrich, Nele [Gutachter] Friedrich und Martin [Gutachter] Reincke. „Metabolische Signaturen des Insulin-like growth factor 1 anhand von Metabolom-Untersuchungen in Plasma und Urin / Henrike Knacke ; Gutachter: Nele Friedrich, Martin Reincke ; Betreuer: Nele Friedrich“. Greifswald : Universität Greifswald, 2019. http://d-nb.info/1202111297/34.
Der volle Inhalt der QuelleLecuyer, Lucie. „Signatures métabolomiques associées au risque à long terme de cancers du sein et de la prostate et à l’alimentation dans la cohorte SU.VI.MAX : Nouveaux horizons ouverts par la métabolomique appliquée à l’épidémiologie nutritionnelle“. Thesis, Paris 13, 2019. http://www.theses.fr/2019PA131023.
Der volle Inhalt der QuelleBreast and prostate cancers are among the cancers with the highest incidence worldwide and notably in Western countries. The main current challenges lie in the improvement of understanding of nutrition/health relationships and in the identification of individuals at higher risk long before the development of overt cancer to set up prevention actions. A variety of factors exert an impact on the onset and progression of cancer. Among these, nutrition appears as a key factor, in that it can be modified and acted upon through interventions. It is therefore crucial to assess its contribution. For this purpose,detailed and accurate assessment of nutritional intake is essential. Metabolomics, allowing the identification of endogenous, exogenous and microbial biomarkers, opens new perspectives in nutritional epidemiology. So far, few have studies investigated the impact of overall diet on metabolism and risk of breast and prostate cancer through metabolomic profiling. As part of this thesis, we conducted nested case-controls and cross-sectional studies within the SU.VI.MAX cohort to highlight plasma signatures of breast and prostate cancer risks and of overall diet. Plasma samples were collected at baseline and were analysed using two complementary methods : mass spectrometry coupled with liquid chromatography and proton nuclear magnetic resonance. Participants dietary habits were estimated using repeated 24h dietary records and socio-demographic and lifestyle data were collected from self-administered questionnaires.These investigations highlighted endogenous and microbial metabolites associated with overall diet as well as candidate biomarkers of specific dietary exposures. We also identified endogenous, exogenous and microbial metabolites associated with breast and prostate cancers risk suggesting a metabolic disruption up to 13 years before cancer diagnostic. Furthermore, diet appears to be implicated in the variation in plasma levels of some metabolites discriminating individuals at higher risk of developing breast or prostate cancers. These results need to be replicated in future independent observational and interventional studies. In the future, the identification of robust metabolic signatures of breast and prostate cancers risk, of the impact of diet on metabolism and carcinogenesis, and food intake would contribute to better understand health and environment relationships, to better estimate nutritional exposure or even to contribute to the set-up of new public health recommendations in order to reduce the incidence of these pathologies
Moro, Joanna. „Impact de la déficience en acides aminés indispensables sur le métabolisme protéique et énergétique, et identification de signatures métaboliques“. Thesis, université Paris-Saclay, 2021. http://www.theses.fr/2021UPASB001.
Der volle Inhalt der QuelleThe availability of protein sources for human nutri-tion is a major concern due to global demographics, economics and nutritional transitions. Protein intakes must cover the need for nine indispensable amino acids (IAA). It is important that this need is met in order to avoid situations of protein and energy me-tabolism imbalance. Various studies have been de-veloped to determine this need: nitrogen balance, the factorial method, and methods using stable iso-topes. However, these methods are difficult and invasive, and the obtained values of needs present significant differences. It is therefore necessary to develop more precise and non-invasive approaches, such as metabolomics, as recommended by the FAO.The objectives of this thesis are to assess the impact of protein and IAA (lysine and threonine) deficiency on protein and energy metabolism and to identify markers of deficiency for these two amino acids in the growing rat. Severe levels of deficiency (85%; 75%) in protein and lysine and threonine decrease weight and lean mass and increase food intake. These effects are associated with a decrease in protein synthesis and an increase in energy metabolism in low protein diets. These effects seems to be mediated by FGF21. Analyses of metabolomics in urine show that variations in pipecolate and taurine indicate lysine and threonine deficiencies, respectively
Sakiou, Sofia. „Caractérisation, traçabilité et contrôle qualité des huiles essentielles de lavandes et de lavandins : Apports des signatures chromatographiques et spectroscopiques“. Thesis, Aix-Marseille, 2015. http://www.theses.fr/2015AIXM4369/document.
Der volle Inhalt der QuelleLavender and lavandin essential oils (EOs) belong to the heritage of the Mediterranean region. Like any natural or synthetic product with an added value, these EOs must be controlled to justify the quality of the product. This quality control requires the establishment of a reliable analytical methodology. In this study, a new approach using spectroscopic and chromatographic techniques for data processing associated to chemometric tools allows to discriminate lavender and lavandin EOs. This discrimination is carried out thanks to their spectroscopic or chromatographic fingerprints. The interest to use the chiral chromatography combined with polarimetric detection and of acquired chiroptical signature was also studied. This methodology has allowed us to identify metabolomic markers which are paramount to characterize the varieties. The results show that it is possible to discriminate the lavender and lavandin EOs according to their varieties with good accuracy on all of the techniques used
Pérez, lanzón María. „Modeling Hormone Receptor Positive Breast Cancer in Immunocompetent Mice Blocking tumor-educated MSC paracrine activity halts osteosarcoma progression Organoids for Modeling Genetic Diseases. In: International Review of Cell and Molecular Biology A preclinical mouse model of osteosarcoma to define the extracellular vesicle-mediated communication between tumor and mesenchymal stem cells Failure of immunosurveillance accelerates aging The metabolomic signature of extreme longevity: Naked mole rats versus mice Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity Laminin-binding integrins are essential for the maintenance of functional mammary secretory epithelium in lactation Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer“. Thesis, université Paris-Saclay, 2021. http://www.theses.fr/2021UPASL019.
Der volle Inhalt der QuelleProgress in breast cancer research relies on the availability of suitable cell lines that can be implanted in immunocompetent laboratory mice. The best explored mouse strain, C57Bl/6, is also the only one for which multiple genetic variants are available. Driven by the fact that no hormone receptor-positive C57Bl/6-derived mammary carcinoma cell lines are available, we decided to establish such cell lines. Breast cancers were induced in female C57BL/6 mice using a synthetic progesterone analogue combined with a DNA damaging agent. Cell lines were established from these tumors and selected for dual (estrogen + progesterone) receptor positivity, as well as transplantability into C57BL/6 females. One cell line, which we called MD5,fulfilled these criteria and allowed for the establishment of poorly differentiated, highly proliferative, immune cold tumors. Such tumors reduced their growth (though did not regress) upon treatment with estrogen receptor antagonists, as well as with anthracyline-based chemotherapy. However, the latter effect was not influenced by T cell depletion and MD tumors failed to respond to PD-1 blockade, suggesting that they are immunologically cold. In conclusion, C57BL/6-derived MD5 cells constitute a model of poor prognosis hormone receptor-positive breast cancer
Bücher zum Thema "Metabolomic signature"
Vermeulen, Roel, Douglas A. Bell, Dean P. Jones, Montserrat Garcia-Closas, Avrum Spira, Teresa W. Wang, Martyn T. Smith, Qing Lan und Nathaniel Rothman. Application of Biomarkers in Cancer Epidemiology. Oxford University Press, 2017. http://dx.doi.org/10.1093/oso/9780190238667.003.0006.
Der volle Inhalt der QuelleBuchteile zum Thema "Metabolomic signature"
Chalikiopoulou, Constantina, José Carlos Gómez-Tamayo und Theodora Katsila. „Untargeted Metabolomics for Disease-Specific Signatures“. In Mass Spectrometry for Metabolomics, 71–81. New York, NY: Springer US, 2022. http://dx.doi.org/10.1007/978-1-0716-2699-3_7.
Der volle Inhalt der QuelleBalikcioglu, Pinar Gumus, und Christopher B. Newgard. „Metabolomic Signatures and Metabolic Complications in Childhood Obesity“. In Contemporary Endocrinology, 343–61. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-68192-4_21.
Der volle Inhalt der QuelleElolimy, Ahmed A., Mohamed Zeineldin, Mohamed Abdelmegeid, Alzahraa M. Abdelatty, Abdulrahman S. Alharthi, Mohammed H. Bakr, Mona M. M. Y. Elghandour, Abdelfattah Z. M. Salem und Juan J. Loor. „Metabolomics and Proteomics Signatures in Feed-Efficient Beef and Dairy Cattle“. In Sustainable Agriculture Reviews, 153–65. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-76529-3_5.
Der volle Inhalt der QuelleCzajkowska, Anna, Ahsan Hameed, Mauro Galli, Muhammad Umair Ijaz, Adam Kretowski und Michal Ciborowski. „Altered Metabolome of Amino Acids Species: A Source of Signature Early Biomarkers of T2DM“. In Biomarkers in Diabetes, 83–125. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-08014-2_5.
Der volle Inhalt der QuelleCzajkowska, Anna, Ahsan Hameed, Mauro Galli, Muhammad Umair Ijaz, Adam Kretowski und Michal Ciborowski. „Altered Metabolome of Amino Acids Species: A Source of Signature Early Biomarkers of T2DM“. In Biomarkers in Diabetes, 1–44. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-81303-1_5-1.
Der volle Inhalt der Quelle„Metabolomics and the Personalized Metabolic Signature“. In Personalized Nutrition, 39–48. CRC Press, 2007. http://dx.doi.org/10.1201/9781420009170-9.
Der volle Inhalt der QuelleGibney, Michael, Marianne Walsh und Lorraine Brennan. „Metabolomics and the Personalized Metabolic Signature“. In Personalized Nutrition, 23–32. CRC Press, 2007. http://dx.doi.org/10.1201/9781420009170.ch3.
Der volle Inhalt der QuelleSuman, Ray. „Proteomics and metabolomics in neuropsychiatry“. In Oxford Textbook of Neuropsychiatry, herausgegeben von Niruj Agrawal, Rafey Faruqui und Mayur Bodani, 105–14. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198757139.003.0010.
Der volle Inhalt der QuelleArjmand, Babak, Sepideh Alavi-Moghadam, Peyvand Parhizkar-Roudsari, Mostafa Rezaei-Tavirani, Akram Tayanloo-Beik, Parisa Goodarzi, Neda Mehrdad, Fereshteh Mohamadi-Jahani und Bagher Larijani. „Metabolomics Signatures of SARS-CoV-2 Infection“. In Advances in Experimental Medicine and Biology. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/5584_2021_674.
Der volle Inhalt der QuelleNiharika, Pedamallu, S. Manohar Babu, A. Mercy, Akula Prabhu Sangeetha und Satya Narayan Tripathy. „MULTI-OMICS TECHNOLOGY BASED BIOMARKERS“. In Futuristic Trends in Biotechnology Volume 2 Book 27, 225–33. Iterative International Publishers, Selfypage Developers Pvt Ltd, 2023. http://dx.doi.org/10.58532/v2bs27p2ch6.
Der volle Inhalt der QuelleKonferenzberichte zum Thema "Metabolomic signature"
González-Domínguez, Raúl, Álvaro González-Domínguez und Alfonso Lechuga-Sancho. „Comparison of the metabolomic signature of diabetes and the oral glucose tolerance test“. In 4th International Electronic Conference on Medicinal Chemistry. Basel, Switzerland: MDPI, 2018. http://dx.doi.org/10.3390/ecmc-4-05571.
Der volle Inhalt der QuelleOnesti, Concetta Elisa, François Boemer, Claire Josse, Ahmed Debit, Christophe Poulet, Vincent Bours und Guy Jerusalem. „Abstract PS17-01: A metabolomic signature as screening method for breast cancer diagnosis“. In Abstracts: 2020 San Antonio Breast Cancer Virtual Symposium; December 8-11, 2020; San Antonio, Texas. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.sabcs20-ps17-01.
Der volle Inhalt der QuelleSelvaraj, Emmanuel, Daniel Radford-Smith, Rory Peters, Kate Lynch, Daniel Anthony, Michael Pavlides, Alessandra Geremia, Adam Bailey, Emma Culver und Fay Probert. „O04 Serum nuclear magnetic resonance metabolomic signature can discriminate immunoglobulin G4-related sclerosing cholangitis and primary sclerosing cholangitis“. In Abstracts of the British Association for the Study of the Liver Annual Meeting, 22–24 November 2021. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2021. http://dx.doi.org/10.1136/gutjnl-2021-basl.4.
Der volle Inhalt der QuelleLiu, Zhongbo, Christopher A. Blair und Xiaolin Zi. „Abstract 4867: The metabolomic signature of Rhodiola rosea L. extracts- (SHR-5) treated mouse bladder cancer in the UPII-mutant Ha-ras transgenic model.“ In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-4867.
Der volle Inhalt der QuelleMoore, A. R., X. Song, J. Roque, C. Perez, S. Battu, R. Vojnik, J. Wilson, J. E. Levitt, R. Zare und A. Rogers. „A Lung-specific Metabolic Signature From Heat and Moisture Exchange (HME) Filter Metabolomic Analysis Is Distinct From Plasma Signal in Acute Respiratory Distress Syndrome“. In American Thoracic Society 2024 International Conference, May 17-22, 2024 - San Diego, CA. American Thoracic Society, 2024. http://dx.doi.org/10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a7210.
Der volle Inhalt der QuelleWong, K., I. Sulaiman, B. G. Wu, B. Kwok, C. R. Barnett, Y. Li, A. Tsirigos et al. „Metabolomic Signatures in Mild COPD“. In American Thoracic Society 2023 International Conference, May 19-24, 2023 - Washington, DC. American Thoracic Society, 2023. http://dx.doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5722.
Der volle Inhalt der QuelleHourmozdi, J., P. J. Leary, D. D. Ralph, S. J. Nolley, S. G. Rayner und S. A. Gharib. „Peripheral Blood Metabolomic Signatures Associated with Mortality in Pulmonary Hypertension“. In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a6353.
Der volle Inhalt der QuelleLabaki, W., Y. Wang, S. Murray, J. Curtis, R. Bowler, C. Pistenmaa, P. Nardelli et al. „Differentiating metabolomic signatures of airway and pulmonary vascular abnormalities in COPD“. In ERS International Congress 2022 abstracts. European Respiratory Society, 2022. http://dx.doi.org/10.1183/13993003.congress-2022.2448.
Der volle Inhalt der QuelleGaul, David A., Christina M. Jones, Maria Eugenia Monge, Long Q. Tran, Martin M. Matzuk, John F. McDonald und Facundo M. Fernandez. „Abstract AS05: Metabolomic signatures in sera from early stage ovarian cancer patients“. In Abstracts: 10th Biennial Ovarian Cancer Research Symposium; September 8-9, 2014; Seattle, WA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1557-3265.ovcasymp14-as05.
Der volle Inhalt der QuellePi, H., L. Xia, D. D. Ralph, S. G. Rayner, A. Shojaie, P. J. Leary und S. A. Gharib. „Metabolomic Signatures Associated with Right Ventricular Dilation and Mortality in Pulmonary Arterial Hypertension“. In American Thoracic Society 2022 International Conference, May 13-18, 2022 - San Francisco, CA. American Thoracic Society, 2022. http://dx.doi.org/10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a3442.
Der volle Inhalt der Quelle